Scopolin

Research use only, not for human use.

Scopolin can reduce the clinical symptoms of rat AIA by inhibiting inflammation and angiogenesis, and this compound may be a potent agent for angiogenesis related diseases and can serve as a structural base for screening more potent synthetic analogs.

Scopolin formation is increased by the enhanced activity of PAL. Scopolin can reduce the clinical symptoms of rat AIA by inhibiting inflammation and angiogenesis, and this compound may be a potent agent for angiogenesis related diseases and can serve as a structural base for screening more potent synthetic analogs.

——

Animal Model:HFD-fed C57BL/6?N miceDosage:0.02% (w/w) in HFD diet (equivalent to 20?mg/kg body weight)Administration:Supplemented in diet, 8 weeks Result:Reversed the HFD-induced hepatic TG, cholesterol, and fatty acid accumulation by 35%, 49%, and 35%, respectively.Reversed the HFD-induced decrease in plasma adiponectin levels by 76%, and reduced the increased plasma MCP-1, TNFα, and IL-6 levels.Restored HFD-induced downregulation of SIRT1 activity.Animal Model:Adjuvant-induced arthritis (AIA) rats Dosage:50, 100 mg/kg Administration:i.p.Result:Inhibited inoculated and non-inoculated paw swelling and articular index scores.Reduced new blood vessels, and reduced IL-6, VEGF and FGF-2 expressions in rat synovial tissues.

Scopolin | Murrayin | Scopoloside

Apoptosis

NF-κB

Others

Inflammation/Immunology

——

531-44-2

354.31

C16H18O9

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (282.24 mM)

COc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2oc(=O)ccc2c1

6-methoxy-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2H-chromen-2-one

(-20℃)

With Ice Pack

≥ 2 years